The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”
The company is paying $350 million upfront, and potentially over $1.3 billion overall, for a radiopharmaceutical for prostate cancer that works differently than Novartis’ Pluvicto.
It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does that mean for your enrollment plan?
A "sub-study" of a large clinical trial found the drug, obicetrapib, significantly reduced levels of a type of tau protein linked to Alzheimer's development.
Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly became a blockbuster medicine following its approval two years ago.
Stronger connections lead to better outcomes. In this infographic, learn how to use key moments in the product lifecycle, from drug discovery to commercialization, to help transform patient care.
